Moomoo AI 已提取核心訊息
Avalo Therapeutics, Inc. has announced the completion of a reverse stock split at a ratio of 1-for-240, effective as of 5:00 p.m. on December 28, 2023. The reverse stock split was previously approved by stockholders on December 20, 2023, and resulted in the reduction of outstanding common stock from approximately 192.4 million shares to approximately 801,611 shares. The action was taken to meet the continued listing criteria for the Nasdaq Capital Market. The company's common stock began trading on a split-adjusted basis on December 29, 2023, under the existing trading symbol 'AVTX'. Stockholders who would have received fractional shares as a result of the reverse stock split were instead given one whole share of common stock. The reverse stock split did not change the number of...Show More
Avalo Therapeutics, Inc. has announced the completion of a reverse stock split at a ratio of 1-for-240, effective as of 5:00 p.m. on December 28, 2023. The reverse stock split was previously approved by stockholders on December 20, 2023, and resulted in the reduction of outstanding common stock from approximately 192.4 million shares to approximately 801,611 shares. The action was taken to meet the continued listing criteria for the Nasdaq Capital Market. The company's common stock began trading on a split-adjusted basis on December 29, 2023, under the existing trading symbol 'AVTX'. Stockholders who would have received fractional shares as a result of the reverse stock split were instead given one whole share of common stock. The reverse stock split did not change the number of authorized shares or the par value per share. Adjustments will be made to the per share exercise price and number of shares issuable under all of the company's outstanding options and warrants, as well as the number of shares authorized and reserved for issuance under the company's equity incentive plan. Equiniti Trust Company, LLC is acting as the exchange agent for the reverse stock split.
Avalo Therapeutics, Inc.宣佈完成反向股票拆分，比例爲1比240，自2023年12月28日下午5點起生效。反向股票拆分此前已於2023年12月20日獲得股東的批准，導致已發行普通股從約1.924億股減少至約801,611股。採取該行動是爲了滿足納斯達克資本市場的持續上市標準。該公司的普通股於2023年12月29日開始按拆分調整後的基礎上交易，現有交易代碼爲 “AVTX”。相反，本來會因反向股票拆分而獲得零股的股東卻獲得了整股普通股。反向股票拆分沒有改變授權股票的數量或每股的面值。將調整公司所有已發行期權和認股權證下的每股行使價和可發行的股票數量，以及根據公司股權激勵計劃批准和預留髮行的股票數量。Equiniti Trust Company, LLC是反向股票拆分的交易所代理。
Avalo Therapeutics, Inc.宣佈完成反向股票拆分，比例爲1比240，自2023年12月28日下午5點起生效。反向股票拆分此前已於2023年12月20日獲得股東的批准，導致已發行普通股從約1.924億股減少至約801,611股。採取該行動是爲了滿足納斯達克資本市場的持續上市標準。該公司的普通股於2023年12月29日開始按拆分調整後的基礎上交易，現有交易代碼爲 “AVTX”。相反，本來會因反向股票拆分而獲得零股的股東卻獲得了整股普通股。反向股票拆分沒有改變授權股票的數量或每股的面值。將調整公司所有已發行期權和認股權證下的每股行使價和可發行的股票數量，以及根據公司股權激勵計劃批准和預留髮行的股票數量。Equiniti Trust Company, LLC是反向股票拆分的交易所代理。
有用
沒用